Clinical Core
Clinical Core
批准号:
10435214
负责人:
Asuncion Mejias
金额:
$29.37万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-01 至 2022-12-19
关键词:
2019-nCoVAgeBiological AssayBloodCOVID-19COVID-19 vaccinationChildClinicalClinical DataClinical DistributionData AnalysesData CollectionDevelopmentDoctor of MedicineEnrollmentGoalsHumanImmuneImmunology procedureInfantInfectionInfluenzaInfluenza vaccinationLifeLongitudinal cohortMeasurementMeasuresPatientsPerformancePrincipal InvestigatorResourcesSARS-CoV-2 infectionSamplingShapesTimeViralViral Load resultViral Respiratory Tract Infectiondata curationdata exchangedata integrationdata managementfollow-upimprovedinfluenza infectioninfluenzavirusnasopharyngeal swabparticipant enrollmentprogramsrespiratorysynergism
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Clinical Core
Principal Investigator: Asuncion Mejias, M.D.
Abstract
This Core will serve three main goals. First, by enrolling all patients, obtaining the human samples, and collecting
the clinical data it will simplify sample organization, data management and compliance with all regulatory aspects
of the U19. In addition, the Clinical Core will support Projects 1 and 2, by performing the viral PCR assays,
which will improve analytical performance and efficiency; and the Data Management Core, by coordinating and
sharing de-identified clinical data.
Specifically, the Core will be responsible for: 1) enrolling infants in the first 6 months of life with influenza or
SARS-CoV-2 infection, as well as healthy non-infected controls, and obtaining sequential blood and respiratory
samples pre and post influenza and COVID-19 vaccination during the first 3 years of life; 2) sample organization
and distribution between Projects (1 and 2); 3) longitudinal clinical data collection, data curation and data
transfer to the Data Management Core for data analyses and integration with all immune assays; 4) measure
influenza and SARS-CoV-2 viral loads by quantitative real-time PCR in clinical samples (nasopharyngeal swabs)
from infants with influenza or SARS-CoV-2 infection. This approach will optimize the use of resources and will
facilitate integration and synergy among all projects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RespiDART 2022: Frontiers in Drug Development against Respiratory Viruses
-
批准号:10609297
-
项目类别:
-
资助金额:$0.65万
-
财政年份:2022
-
负责人:Asuncion Mejias
-
依托单位:
Clinical Core
-
批准号:10599207
-
项目类别:
-
资助金额:$31.84万
-
财政年份:2022
-
负责人:Asuncion Mejias
-
依托单位:
Immune Profiles as Markers of Safe and Protective RSV Vaccines
-
批准号:9217574
-
项目类别:
-
资助金额:$15.13万
-
财政年份:2015
-
负责人:Asuncion Mejias
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: